Top in hem/onc: HPV vaccine and cervical cancer, diet and exercise for cancer survivors
Recent evidence indicates that mortality due to cervical cancer may have decreased as much as 50% among younger populations vaccinated against HPV. A video discussion of the data was the top story in hematology/oncology last week.
Another top story included dietary and physical activity suggestions for cancer survivors. David L. Jennings II, MSN, RN, AGPCNP-BC, a nurse practitioner at Levine Cancer Institute at Atrium Health and a HemOnc Today Editorial Board member, recommended daily exercise and adjusting food portions during and after chemotherapy. However, health plans should be individualized to meet patient needs, he added.

Read these and more top stories in hematology/oncology below:
HPV vaccination results in ‘real’ reduction in cervical cancer
In the second installment of a four-video series timed to Cervical Cancer Awareness Month, Maurie Markman, MD, spoke with Healio about the impact of HPV vaccination on the global burden of cervical cancer. Read more.
Top diet, exercise recommendations for cancer survivors
In his own practice, Jennings said that patients frequently ask what they can do to stay healthy and keep their disease from returning following completion of therapy. Read more.
FDA grants fast track designation to natural killer cell therapy for GI cancers
The FDA granted fast track designation to CYNK-101, a natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma. Read more.
Oncologist makes career move to industry to help solve inequities in cancer care
Neelima Denduluri, MD, moved from a large breast oncology practice and research in clinical trials to industry because she sought to expand her skill set and greaten her impact. Read more.
Gilead withdraws Zydelig indication for lymphoma, leukemia subtypes
Gilead Sciences has decided to voluntarily withdraw its accelerated approval of idelalisib for two blood cancer indications. Read more.